N/A
Completed N=504
Optimizing Aspirin and Clopidogrel Therapy (BOchum CLopidogrel and Aspirin Plan)
Source: ClinicalTrials.gov NCT01212302 ↗Enrolled (actual)
504
Serious AEs
0.0%
Results posted
Sep 2011
Primary outcomePrimary: Number of Participants Who Were Responders or Low-Responders of Antiplatelet Therapy as a Result of Whole Blood Aggregometry Testing (See Outcome Measure Description) — 155 participants
Summary
Dual antiplatelet therapy with acetylsalicylic acid (ASA, aspirin) and clopidogrel is of great importance for treatment following coronary stenting. Unfortunately the variable platelet inhibitory effectiveness compromises the antithrombotic benefit of dual antiplatelet therapy. The aim of this prospective single centre study was to reduce the low response incidence of dual antiplatelet therapy with ASA and clopidogrel based on a standardized therapy algorithm.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Who Were Responders or Low-Responders of Antiplatelet Therapy as a Result of Whole Blood Aggregometry Testing (See Outcome Measure Description) |
155 | — |
Eligibility Criteria
Inclusion Criteria
- Patients with stable coronary artery disease (CAD) or acute coronary syndromes (ACS) following percutaneous coronary intervention (PCI)
Exclusion Criteria
- abnormal platelet count in patients,
- severe liver disorders,
- current gastrointestinal disorders,
- current infections,
- congestive heart failure,
- known bleeding disorders,
- treatment with bivalirudin or glycoprotein IIb/IIIa antagonists within the last 7 days.
Data sourced from ClinicalTrials.gov (NCT01212302). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.